Rankings
▼
Calendar
MDGL Q4 2023 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$117M
Net Income
-$112M
EPS (Diluted)
$-5.68
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$80M
Free Cash Flow
-$81M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$641M
Total Liabilities
$235M
Stockholders' Equity
$405M
Cash & Equivalents
$100M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$117M
-$85M
-37.4%
Net Income
-$112M
-$86M
-30.6%
← FY 2023
All Quarters
Q1 2024 →